Top Markets
Coin of the day
Curatis Holding AG Curatis Holding AG

Curatis Holding AG

CURN
Classement en actions #20206
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical... Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized medical conditions. The company's extensive product offerings span a broad array of therapeutic areas. These encompass treatments for antiplatelet conditions, metastatic hormone receptor-positive breast cancer, anti-arrhythmic disorders, nasal oil applications, Wilson's disease, antidotes for cyanide poisoning and digoxin toxicity, antihypotensive agents, therapies for bladder pain syndrome/interstitial cystitis, antibiotics, diagnostic tools for ophthalmology, antivirals, ophthalmic/antibiotic combinations, gentamycin collagen sponges, solutions for benign prostatic hyperplasia, immunomodulators, treatments for epilepsy and essential tremor, thyreostatics, therapies for hereditary tyrosinemia type 1, gastroenterological products, additional immunomodulators and thyreostatics, tranquilizers, Helicobacter pylori tests, phosphate binders, specialized nutritional support for dialysis patients, dermatological corticosteroids, antidotes for lead and mercury poisoning, corticostimulants, anti-fog agents, treatments for chorea associated with Huntington's disease, and antiepileptics. In addition to its commercialized portfolio, Curatis is actively engaged in developing new pharmaceutical compounds. Its pipeline includes C-PTBE-01, currently in Phase IIb clinical trials for treating peritumoral brain edema in pediatric patients; C-AM-01, undergoing Phase IIa trials for preventing severe migraine with aura; and C-MOH-01, also in Phase IIa for the treatment and prevention of medication overuse headache. Furthermore, KIN001 is in Phase I clinical trials, targeting rare inflammatory and fibrotic diseases. The company maintains its headquarters in Liestal, Switzerland.
Prix de l'action
$25.88
Capitalisation boursière
$137.20M
Changement (1 jour)
2.05%
Changement (1 an)
87.77%
Pays
CH
Échange Curatis Holding AG (CURN)

Catégorie

Historique du prix de l'action pour Curatis Holding AG (CURN)
Prix de clôture le plus élevé : $25.29 le 2026-08-01

Prix de clôture le plus bas : $1.26M le 1999-04-01
Historique du prix de l'action de Curatis Holding AG de 1999 à 2026
Performance annuelle du prix de l'action
Année Performance
2026 (TTM) 54.44%
2025 2.02%
2024 524.76%
2023 -95.88%
2022 -83.81%
2021 -17.34%
2020 481.84%
2019 37.23%
2018 -52.65%
2017 -17.39%
2016 -30.62%
2015 -47.06%
2014 -44.60%
2013 13.03%
2012 8.19%
2011 -47.25%
2010 -0.13%
2009 146.64%
2008 -94.83%
2007 -25.49%
2006 -36.45%
2005 -14.30%
2004 -19.20%
2003 8.14%
2002 88.71%
2001 -91.53%
2000 -89.36%
1999 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
$171.67 -
DE
$164.46 25.10%
DE
$37.82 21.13%
JP
$222.79 32.01%
CH
$21.08 12.12%
IN